Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation

被引：0
作者：
Kaito Harada
机构：
[1] Tokai University School of Medicine,Department of Hematology and Oncology
来源：
International Journal of Hematology | 2023年 / 118卷
关键词：
Donor lymphocyte infusion; Cell therapy; Allogeneic stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Donor lymphocyte infusion (DLI) is an allogenic immunotherapy used after allogeneic hematopoietic stem cell transplantation. DLI takes advantage of the graft-versus-tumor effect induced by the infused CD3 + T cells, but may induce graft-versus-host disease. To date, DLI has been attempted to prevent hematological relapse after allogeneic hematopoietic stem cell transplantation in patients with mixed chimerism and molecular relapse (pre-emptive DLI), and as maintenance therapy in patients with high-risk hematological malignancies (prophylactic DLI). DLI response and efficacy depend on patient, disease, and DLI factors. This review discusses the efficacy and risks of DLI, with a focus on pre-emptive and prophylactic use.
引用
收藏
页码：158 / 168
页数：10
相关论文
共 381 条
[1]  
Schmid C(2018)Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation Haematologica 103 237-245
[2]  
de Wreede LC(2012)Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation Blood 119 1599-1606
[3]  
van Biezen A(2015)Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study Biol Blood Marrow Transplant 21 454-459
[4]  
Finke J(2021)Treatment of AML relapse after allo-HCT Front Oncol 11 812207-1146
[5]  
Ehninger G(2019)Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders Int J Cancer 144 1135-1359
[6]  
Ganser A(2018)Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after Allo-HSCT Biol Blood Marrow Transplant 24 1350-4945
[7]  
Schmid C(2007)Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party J Clin Oncol 25 4938-1790
[8]  
Labopin M(2014)Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation Biol Blood Marrow Transplant 20 1785-944
[9]  
Nagler A(2017)Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the japan marrow donor program Biol Blood Marrow Transplant 23 938-444
[10]  
Niederwieser D(1997)Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 433-568
12345678910